



U.S. Food and Drug Administration  
Protecting and Promoting Public Health

[www.fda.gov](http://www.fda.gov)

# Personalized Medicine: What's New and Interesting at FDA

Elizabeth Mansfield, PhD  
OIVD/CDRH/FDA  
FDA IVD Roundtable  
7 June 2012



# How is FDA addressing Personalized Medicine?

- Personalized Medicine
  - Companion Diagnostics
    - Policy and practice
    - Internal and external
  - Novel Technologies
    - UHTP (next-gen) sequencing
    - Array-based CNV
    - Proteomics
  - Policy Issues
    - LDTs
    - RUOs
    - various
  - Scientific Questions



# FDA's View of Personalized Medicine

- Commissioner Hamburg
  - Committed to Personalized Medicine program
- Dr. Spielberg
  - Assigned to manage three medical product centers
  - Personal interest in personalized medicine
  - Initiating OC coordination of personalized medicine in product centers
- CDRD/CDER/CBER
  - Working together to identify issues, create solutions
    - Internal practices
    - External guidance



# CDRH Role in Personalized Medicine

- In CDRH
  - Personalized Medicine Staff
    - 4 dedicated staff in PM
    - ~10 review staff in review divisions
    - CMO
  - Current scope is IVDs, with other device issues as needed
  - Priority for CDRH, but requires careful approach within current laws/regulations



# Current PM Activities

- Draft Companion Dx guidance
  - published July 2011
  - plan to finalize 2Q2012
- Preparing “Codevelopment Guidance”
  - Many interesting issues
  - Not a “how to” but a general guide
- Other guidances, e.g. Trial Enrichment
- Internal policy building
  - Centers’ roles in decision-making
  - Cross-center communications
  - Timing/coordination
  - Consistency and quality of reviews



# More Personalized Medicine

- Emerging technologies
  - Next-gen sequencing
    - Approaches to regulation—targeted, whole exome, whole genome
    - Standards
  - Array-based testing
  - Proteomics
  - Innovation Pathway



# Recent Approvals and What We've Learned

- Vemurafinib
  - Approved prior to PDUFA and MDUFMA dates
  - Marker positive trials
  - CDER and CDRH worked in coordinated manner with sponsors, internally
  - Issues:
    - Differing review timelines
    - Differing times of availability for drug/diagnostic
    - Some unexpected issues in Dx (resolved)

Outcome: Successful codevelopment



# Recent Approvals and What We've Learned (2)

- Crizotinib
  - Approved prior to PDUFA and MDUFMA dates
  - Marker positive trials, very small population
  - CDRH and CDER worked in coordinated manner with sponsors, internally
  - Issues:
    - Review timelines very compressed
    - Issues in clinical trial testing (resolved but with lessons learned)
    - Postmarket studies
  - Outcome: Successful codevelopment





# Lessons as Result of Two Approvals

- Accelerated drug approval does not significantly change when companion Dx needed
- Intercenter communication was highly effective and review staff worked well together
  - Co-attendance at meetings
  - Questions transmitted in timely manner
  - Approvals and press well-coordinated
  - *Generalize the model*
- Drug and Dx sponsors should carefully define expectations for each other
- Modular PMA process for Dx highly preferred over traditional
- Codevelopment works!



# Intercenter Policies and Communications

- Different Centers have different laws, regulations, cultures, and needs
- Positive developments:
  - Working in close proximity with each other
  - Inviting each center to others' meetings
    - See the big picture, warts and all
  - Identifying issues together and creating draft policy
  - Regular internal interactions on broader scope
  - One internal SOP nearly finalized



## Other Intercenter Advances

- Creating agreed-to ways of working together
- Recognizing each Center's role in process
  - Including limitations
- Creating streamlined regulatory communication methods
  - Different centers use different systems to archive, track submissions
- Recognition of status of tests in INDs




# Prognosis and Predictions

- Progress is rapid, but still has its unpredictable moments
- Everyone playing well together
  - Each center learning a lot from the other
- Sense that system will work
  - New lessons from every new model
- Greater internal uniformity already in place
- Guidance lagging submissions as we learn
- System operational but still needs some refinement
- Sponsors “getting it”
- THIS WILL WORK




# Pre-IDE and IDE submissions to OIVD 2007-2012





# Consults from CDER, CBER





**U.S. Food and Drug Administration**  
Protecting and Promoting Public Health

[www.fda.gov](http://www.fda.gov)

- Thanks!
- [Elizabeth.mansfield@fda.hhs.gov](mailto:Elizabeth.mansfield@fda.hhs.gov)